These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2906066)

  • 21. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases.
    Chouinard G; Annable L; Ross-Chouinard A; Mercier P
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):21S-26S. PubMed ID: 3220967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model.
    Singh MM; Becker RE; Pitman RK; Nasrallah HA; Lal H; Dufresne RL; Weber SS; McCalley-Whitters M
    Biol Psychiatry; 1982 Jun; 17(6):729-42. PubMed ID: 6125219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacologic relationship of antisaccade and dyskinesia in schizophrenic patients.
    Cassady SL; Thaker GK; Tamminga CA
    Psychopharmacol Bull; 1993; 29(2):235-40. PubMed ID: 8290671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.
    Akbostanci MC; Atbaşoğlu EC; Balaban H
    Acta Neurol Belg; 1999 Sep; 99(3):176-81. PubMed ID: 10544725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.
    Fu Y; Fan CH; Deng HH; Hu SH; Lv DP; Li LH; Wang JJ; Lu XQ
    Acta Pharmacol Sin; 2006 Mar; 27(3):328-32. PubMed ID: 16490169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tardive dyskinesia and plasma homovanillic acid.
    Moore DC; Glazer WM; Bowers MB; Heninger GR
    Biol Psychiatry; 1983 Dec; 18(12):1393-402. PubMed ID: 6140961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum interferon in schizophrenia.
    Rimón R; Ahokas A; Hintikka J; Heikkilä L
    Ann Clin Res; 1985; 17(4):139-40. PubMed ID: 4073801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
    Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
    Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.
    Kang SG; Choi JE; An H; Lim SW; Lee HJ; Han C; Kim YK; Kim SH; Cho SN; Lee MS; Joe SH; Jung IK; Kim L
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1545-8. PubMed ID: 18602732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tardive dyskinesia in outpatient schizophrenics treated with depot phenothiazines.
    Williams R; Naya A; Dalby JT
    J Clin Psychopharmacol; 1986 Oct; 6(5):318-9. PubMed ID: 3771819
    [No Abstract]   [Full Text] [Related]  

  • 31. Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia.
    Monteleone P; Maj M; Ariano MG; Iovino M; Fiorenza L; Steardo L
    Psychopharmacology (Berl); 1988; 96(2):223-6. PubMed ID: 3148149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum vitamin B6 in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C; Lerner V; Cohen H; Kotler M
    Clin Neuropharmacol; 2000; 23(4):212-5. PubMed ID: 11020126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients.
    Smith RC; Tamminga CA; Crayton JW; Dekirmenjian H; Davis JM
    Psychopharmacology (Berl); 1979; 66(1):29-33. PubMed ID: 44374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The plasma phenylalanine/large neutral amino acid ratio: a risk factor for tardive dyskinesia.
    Richardson MA; Suckow R; Whittaker R; Boggiano W; Sziraki I; Kushner H; Perumal A
    Psychopharmacol Bull; 1989; 25(1):47-51. PubMed ID: 2772116
    [No Abstract]   [Full Text] [Related]  

  • 35. Serum concentration of depot neuroleptics in tardive dyskinesia.
    Fairbairn AF; Rowell FJ; Hui SM; Hassanyeh F; Robinson AJ; Eccleston D
    Br J Psychiatry; 1983 Jun; 142():579-83. PubMed ID: 6882980
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of symptomatology of schizophrenia and tardive dyskinesia.
    Perenyi A; Norman T; Burrows GD
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):51-5. PubMed ID: 1638174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia.
    Liu H; Kang Y; Liang J; Li C; Xiu M; Chen D; Yang F; Wang F; Wu G; Haile CN; Kosten TA; Kosten TR; Zhang XY
    Psychiatry Res; 2012 Jul; 198(2):329-31. PubMed ID: 22417931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Butaperazine pharmacokinetics in tardive dyskinesia.
    Wolf ME; Javaid JI; Mosnaim AD; Davis JM
    Biopharm Drug Dispos; 1985; 6(2):223-7. PubMed ID: 2860932
    [No Abstract]   [Full Text] [Related]  

  • 39. Defect symptoms and abnormal involuntary movement in schizophrenia.
    Iager AC; Kirch DG; Jeste DV; Wyatt RJ
    Biol Psychiatry; 1986 Jul; 21(8-9):751-5. PubMed ID: 2873845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A cell membrane correlate of tardive dyskinesia in patients treated with phenothiazines.
    Zubenko GS; Cohen BM
    Psychopharmacology (Berl); 1986; 88(2):230-6. PubMed ID: 2869541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.